quantisnow
FeedTopReportsPricing
⌘K
Live feed
17:24:59·91d
INSIDERFiling
NewAmsterdam Pharma Company N.V. logo

Chief Financial Officer Somaiya Mayur Ian exercised 100,000 units of Ordinary Shares at a strike of $9.26 and sold $3,260,618 worth of Ordinary Shares (100,000 units at $32.61) (SEC Form 4)

NAMS· NewAmsterdam Pharma Company N.V.
Health Care
Original source

Companies

  • NAMS
    NewAmsterdam Pharma Company N.V.
    Health Care

Recent analyst ratings

  • Mar 18UpdateTruist$57.00
  • Oct 20UpdateH.C. Wainwright$52.00
  • Aug 25UpdateWells Fargo$45.00
  • Jul 17UpdateGoldman$27.00
  • Jun 17UpdateCitigroup$42.00
  • Jun 10UpdateStifel$44.00

Related

  • SEC4d
    SEC Form PRE 14A filed by NewAmsterdam Pharma Company N.V.
  • ANALYST36d
    Truist initiated coverage on NewAmsterdam Pharma with a new price target
  • INSIDER42d
    Director Lange Louis G sold $1,357,230 worth of Ordinary Shares (44,619 units at $30.42), decreasing direct ownership by 81% to 10,360 units (SEC Form 4)
  • SEC43d
    SEC Form 144 filed by NewAmsterdam Pharma Company N.V.
  • INSIDER44d
    Director Lange Louis G sold $828,950 worth of Ordinary Shares (28,186 units at $29.41) and exercised 44,619 in-the-money units of Ordinary Shares at a strike of $11.50, increasing direct ownership by 431% to 54,979 units (SEC Form 4)
  • INSIDER45d
    Chief Scientific Officer Kastelein Johannes Jacob Pieter converted options into 300,000 units of Ordinary Shares and sold $9,090,868 worth of Ordinary Shares (300,000 units at $30.30) (SEC Form 4)
  • SEC48d
    SEC Form 144 filed by NewAmsterdam Pharma Company N.V.
  • INSIDER52d
    Chief Executive Officer Davidson Michael H. converted options into 443,707 units of Ordinary Shares and sold $14,753,258 worth of Ordinary Shares (443,707 units at $33.25) (SEC Form 4)
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022